ArticleScientific reports2026
Beyond intraocular pressure: introducing a novel glaucoma-specific PROM for evaluating outcomes after IStent inject implantation combined with phacoemulsification cataract surgery.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
This study aimed to develop and validate a glaucoma-specific patient-reported-outcome-measure (PROM) questionary to assess disease-specific burden across all severities of open-angle glaucoma (OAG), including patients undergoing combined IStent inject micro-bypass and cataract surgery.
methodsA cross-sectional, survey-based study was conducted among adults diagnosed with glaucoma, including members of the AGAF (Asociación-Glaucoma para Afectados y Familiares) and patients from two tertiary hospitals who had undergone combined trabecular micro-bypass (TMB) and phacoemulsification surgery. Patients were stratified into mild, moderate, or severe glaucoma groups based on responses to a glaucoma-specific PROM questionnaire. The primary objective was to assess patient perspectives on visual function, quality of life, and treatment satisfaction.
resultsA total of 240 participants were included (57.5% female; 58.8% diagnosed > 10 years ago). Most patients (61.7%) had moderate glaucoma. Advanced disease was significantly associated with worse self-perceived visual ability, lower quality of life, increased physical and emotional burden, and decreased satisfaction with treatment (all p < 0.0001). Awareness of glaucoma prior to diagnosis was generally low, but post-diagnosis treatment knowledge was higher among those with milder disease. Functional dependence and socioeconomic impact increased with disease severity. Among TMB-treated patients (n = 35), 97% reported no adverse events or discomfort, and 94.3% expressed confidence in their prognosis. Quality of life and satisfaction post-surgery were high across severity levels.
conclusionsDisease severity and delayed diagnosis negatively affect patients' experiences and outcomes. Early detection and intervention are critical. Combined cataract and TMB surgery with IStent Inject was associated with high satisfaction and minimal adverse effects within this patient-reported framework.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.